Viagene Inc. of San Diego has named R. Jefferson Works vicepresident and chief financial officer, and Steven Joseph Mento,Ph.D., vice president of research and development, completingits management team. Works was senior vice president and CFOat Cetus Corp. Mento was director of viral vaccine R&D atLederle-Praxis Biologicals. Viagene is developing drugs basedupon gene transfer technology.
BioCryst Pharmaceuticals Inc. of Birmingham, Ala., hasappointed John P Warnick chief financial officer. Warnick wasCFO of the Belmac Corp. BioCryst focuses on structure-baseddrug design.
Immunology Ltd. of Cambridge, United Kingdom, named Dr.Paul Haycock chief executive officer, replacing William Duncan,who will continue as chairman. Haycock was managing directorof Dunphar Laboratories Ltd. Immunology Ltd. is developingtherapeutics in the field of immunology.
Cor Therapeutics Inc. has appointed Laura A. Brege vicepresident of finance and chief financial officer. She replaces R.Lee Douglas Jr., who will continue as vice president of corporatedevelopment. Brege was vice president of finance and CFO ofComputer Aided Service Inc. Cor (NASDAQ:CORR) of South SanFrancisco, Calif., is focused on products for treatment andprevention of acute cardiovascular diseases.
(c) 1997 American Health Consultants. All rights reserved.